“dravet-syndrome” Archives

in
Entry Author Date Location
With Phase 2 Data in Hand, Ovid Eyes Multiple Pivotal Trials for Epilepsy Drug 09/30/20 New York
Biotech Roundup: FDA Culpa, Tricida Trips, Freenome’s Funding & More 08/28/20 National
Bio Roundup: COVID-19 Trials, Esperion’s Approvals, NASH News & More 02/28/20 National
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More 09/27/19 National
Bio Roundup: Merger Drama, FDA Trauma, Big IPOs, CRISPR Fights & More 06/28/19 National
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits 06/26/19 San Francisco
Stoke Therapeutics Upsizes IPO, Raises $142M for Dravet Drug R&D 06/18/19 Boston
Stoke Therapeutics Preps IPO to Bring Dravet Syndrome Drug to Clinic 05/24/19 Boston
FDA Refuses to Review Zogenix Seizure Drug, Says File Not Complete 04/08/19 San Francisco
With $90M Round, Stoke Eyes a “Spinraza For Epilepsy” And a 2019 IPO 10/23/18 Boston
Bio Roundup: Pfizer’s Prices, Novartis Cuts, Gene Therapy Guide & More 07/13/18 National
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug 07/12/18 San Francisco
With $75M Haul, Ovid Continues Flurry of Biotech IPOs 05/04/17 New York
With Ovid IPO, Ex-Teva CEO Levin Pitches Neuro Drug Plan to Wall Street 04/11/17 New York
Hunting For Pharma Deals, Ovid Bags Epilepsy Drug from Takeda 01/18/17 New York
Levin Steps in as Ovid CEO, Confirms Plan to Target Rare Neuro Diseases 04/16/15 New York
West Coast Biotech Roundup: Amgen, Inslee, Fibrogen, Receptos & More 10/30/14 Seattle
Page 1 of 1